{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-012074","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2024-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.848701+00:00","generated_at":"2026-06-03T22:58:21.571275+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Reviva gains FDA alignment on Phase 3 RECOVER-2 study for brilaroxazine in schizophrenia","bullets":["FDA accepts 4-week RECOVER-2 study; two positive Phase 3 studies plus 12-month safety could support NDA.","Topline data from 1-year OLE long-term safety trial expected Q4 2024; NDA submission targeted by Q3 2025.","RECOVER-2 is a 450-patient global Phase 3 trial; primary endpoint is PANSS total score change at Day 28.","Company plans to initiate first clinical site in Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-012074","json":"https://secwatch.observer/filing/0001437749-24-012074.json","markdown":"https://secwatch.observer/filing/0001437749-24-012074.md","text":"https://secwatch.observer/filing/0001437749-24-012074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924012074/0001437749-24-012074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924012074/rvph20240415_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:58:21.571275+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}